Toll Free: 1-888-928-9744

Asthma - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 613 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Asthma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Asthma - Pipeline Review, H1 2017, provides an overview of the Asthma (Respiratory) pipeline landscape.

Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow air to come in and out of the lungs. Symptoms include shortness of breath, chest tightness or pain, chronic coughing and trouble sleeping due to coughing or wheezing. The predisposing factors include family history, overweight, smoking, exposure to exhaust fumes or other types of pollution and exposure to occupational triggers, such as chemicals used in farming, hairdressing and manufacturing. Treatment includes inhaled corticosteroids, leukotriene modifiers, antihistamines and decongestants. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Asthma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Asthma (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Asthma (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Asthma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 14, 45, 33, 1, 123 and 25 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 25 and 7 molecules, respectively.

Asthma (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Asthma (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Asthma (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Asthma (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Asthma (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Asthma (Respiratory)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Asthma (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Asthma (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 Introduction 7 Asthma - Overview 8 Asthma - Therapeutics Development 9 Asthma - Therapeutics Assessment 39 Asthma - Companies Involved in Therapeutics Development 57 Asthma - Drug Profiles 118 Asthma - Dormant Projects 547 Asthma - Discontinued Products 568 Asthma - Product Development Milestones 574 Appendix 585
List of Tables
Number of Products under Development for Asthma, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Asthma - Pipeline by 4D Pharma PLC, H1 2017 Asthma - Pipeline by AB Science SA, H1 2017 Asthma - Pipeline by AbbVie Inc, H1 2017 Asthma - Pipeline by Abeome Corp, H1 2017 Asthma - Pipeline by Accolade Pharmaceuticals LLC, H1 2017 Asthma - Pipeline by Adamis Pharmaceuticals Corp, H1 2017 Asthma - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2017 Asthma - Pipeline by Advinus Therapeutics Ltd, H1 2017 Asthma - Pipeline by ALK-Abello A/S, H1 2017 Asthma - Pipeline by Allergopharma GmbH & Co KG, H1 2017 Asthma - Pipeline by Almirall SA, H1 2017 Asthma - Pipeline by Alteogen Inc, H1 2017 Asthma - Pipeline by Amakem NV, H1 2017 Asthma - Pipeline by Amgen Inc, H1 2017 Asthma - Pipeline by AnaptysBio Inc, H1 2017 Asthma - Pipeline by AnGes MG Inc, H1 2017 Asthma - Pipeline by Antisense Therapeutics Ltd, H1 2017 Asthma - Pipeline by Apollo Endosurgery Inc, H1 2017 Asthma - Pipeline by ARA Healthcare Pvt Ltd, H1 2017 Asthma - Pipeline by Ario Pharma Ltd, H1 2017 Asthma - Pipeline by ASIT Biotech SA, H1 2017 Asthma - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2017 Asthma - Pipeline by Astellas Pharma Inc, H1 2017 Asthma - Pipeline by AstraZeneca Plc, H1 2017 Asthma - Pipeline by Asubio Pharma Co Ltd, H1 2017 Asthma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Asthma - Pipeline by Axikin Pharmaceuticals Inc, H1 2017 Asthma - Pipeline by Bioncotech Therapeutics SL, H1 2017 Asthma - Pipeline by Biotec Pharmacon ASA, H1 2017 Asthma - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Asthma - Pipeline by CalciMedica Inc, H1 2017 Asthma - Pipeline by Celldex Therapeutics Inc, H1 2017 Asthma - Pipeline by Cellular Biomedicine Group Inc, H1 2017 Asthma - Pipeline by Celon Pharma SA, H1 2017 Asthma - Pipeline by Chiesi Farmaceutici SpA, H1 2017 Asthma - Pipeline by Circassia Pharmaceuticals Plc, H1 2017 Asthma - Pipeline by Cognosci Inc, H1 2017 Asthma - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017 Asthma - Pipeline by Cynata Therapeutics Ltd, H1 2017 Asthma - Pipeline by Cytokinetics Inc, H1 2017 Asthma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Asthma - Pipeline by Denceptor Therapeutics Ltd, H1 2017 Asthma - Pipeline by Enterprise Therapeutics Ltd, H1 2017 Asthma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Asthma - Pipeline by Foresee Pharmaceuticals LLC, H1 2017 Asthma - Pipeline by Fountain Biopharma Inc, H1 2017 Asthma - Pipeline by Genentech Inc, H1 2017 Asthma - Pipeline by GlaxoSmithKline Plc, H1 2017 Asthma - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 Asthma - Pipeline by Griffin Discoveries BV, H1 2017 Asthma - Pipeline by Han Wha Pharma Co Ltd, H1 2017 Asthma - Pipeline by Hydra Biosciences Inc, H1 2017 Asthma - Pipeline by iCeutica Inc, H1 2017 Asthma - Pipeline by iCo Therapeutics Inc., H1 2017 Asthma - Pipeline by Immupharma Plc, H1 2017 Asthma - Pipeline by InKemia IUCT Group SA, H1 2017 Asthma - Pipeline by Intech Biopharm Ltd, H1 2017 Asthma - Pipeline by Invion Ltd, H1 2017 Asthma - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 Asthma - Pipeline by Johnson & Johnson, H1 2017 Asthma - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 Asthma - Pipeline by KPI Therapeutics Inc, H1 2017 Asthma - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 Asthma - Pipeline by Lead Discovery Center GmbH, H1 2017 Asthma - Pipeline by MedImmune LLC, H1 2017 Asthma - Pipeline by Merck & Co Inc, H1 2017 Asthma - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017 Asthma - Pipeline by Mundipharma International Ltd, H1 2017 Asthma - Pipeline by Mycenax Biotech Inc, H1 2017 Asthma - Pipeline by NAL Pharmaceuticals Ltd, H1 2017 Asthma - Pipeline by NeoPharm Co Ltd, H1 2017 Asthma - Pipeline by Novartis AG, H1 2017 Asthma - Pipeline by Omeros Corp, H1 2017 Asthma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Asthma - Pipeline by OPKO Health Inc, H1 2017 Asthma - Pipeline by Orbis Biosciences Inc, H1 2017 Asthma - Pipeline by Orchid Pharma Ltd, H1 2017 Asthma - Pipeline by Orion Oyj, H1 2017 Asthma - Pipeline by Oxagen Ltd, H1 2017 Asthma - Pipeline by Palatin Technologies Inc, H1 2017 Asthma - Pipeline by Panacea Biotec Ltd, H1 2017 Asthma - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2017 Asthma - Pipeline by Pfizer Inc, H1 2017 Asthma - Pipeline by Pharmaxis Ltd, H1 2017 Asthma - Pipeline by Pieris Pharmaceuticals Inc, H1 2017 Asthma - Pipeline by Polyphor Ltd, H1 2017 Asthma - Pipeline by Progenra Inc, H1 2017 Asthma - Pipeline by Promedior Inc, H1 2017 Asthma - Pipeline by Prommune Inc, H1 2017 Asthma - Pipeline by Pulmagen Therapeutics LLP, H1 2017 Asthma - Pipeline by Pulmatrix Inc, H1 2017 Asthma - Pipeline by Pulmokine Inc, H1 2017 Asthma - Pipeline by Qu Biologics Inc, H1 2017 Asthma - Pipeline by Qurient Co Ltd, H1 2017 Asthma - Pipeline by Re-Pharm Ltd, H1 2017 Asthma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Asthma - Pipeline by Respiratorius AB, H1 2017 Asthma - Pipeline by ReveraGen BioPharma Inc, H1 2017 Asthma - Pipeline by Rhizen Pharmaceuticals SA, H1 2017 Asthma - Pipeline by Saje Pharma LLC, H1 2017 Asthma - Pipeline by Shire Plc, H1 2017 Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017 Asthma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017 Asthma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Asthma - Pipeline by Sunovion Pharmaceuticals Inc, H1 2017 Asthma - Pipeline by Swecure AB, H1 2017 Asthma - Pipeline by Synermore Biologics Co Ltd, H1 2017 Asthma - Pipeline by Syntrix Biosystems Inc, H1 2017 Asthma - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017 Asthma - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 Asthma - Pipeline by Therabron Therapeutics Inc, H1 2017 Asthma - Pipeline by Theravance Biopharma Inc, H1 2017 Asthma - Pipeline by Tolerys SA, H1 2017 Asthma - Pipeline by United BioPharma Inc, H1 2017 Asthma - Pipeline by Vectura Group Plc, H1 2017 Asthma - Pipeline by Verona Pharma Plc, H1 2017 Asthma - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017 Asthma - Pipeline by Xencor Inc, H1 2017 Asthma - Pipeline by Yungjin Pharm Co Ltd, H1 2017 Asthma - Dormant Projects, H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..1), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..2), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..3), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..4), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..5), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..6), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..7), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..8), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..9), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..10), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..11), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..12), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..13), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..14), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..15), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..16), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..17), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..18), H1 2017 Asthma - Dormant Projects, H1 2017 (Contd..19), H1 2017 Asthma - Discontinued Products, H1 2017 Asthma - Discontinued Products, H1 2017 (Contd..1), H1 2017 Asthma - Discontinued Products, H1 2017 (Contd..2), H1 2017 Asthma - Discontinued Products, H1 2017 (Contd..3), H1 2017 Asthma - Discontinued Products, H1 2017 (Contd..4), H1 2017 Asthma - Discontinued Products, H1 2017 (Contd..5), H1 2017



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2500
Multi User - US $5000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify